3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Cisplatin
141
Radiotherapy
115
Cetuximab
95
Docetaxel
69
Radiotherapy, Intensity-Modulated
55
Carboplatin
47
pembrolizumab
46
Surveys and Questionnaires
46
Paclitaxel
41
Fluorouracil
39
Radiation
29
Blood Specimen Collection
27
Drug Therapy
26
Erlotinib Hydrochloride
23
Nivolumab
21
Surgical Procedures, Operative
17
Standard of Care
16
Magnetic Resonance Spectroscopy
16
Radiosurgery
14
Pemetrexed
14
Gemcitabine
14
Everolimus
13
Celecoxib
13
durvalumab
12
Low-Level Light Therapy
12
Immunohistochemistry
12
Cyclophosphamide
12
Capecitabine
12
Amifostine
12
Chemoradiotherapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Head and Neck Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled